Covax to purchase 40M doses of Pfizer, BioNTech COVID-19 vaccine

By The Science Advisory Board staff writers

The Covax global vaccine initiative has reached a deal with Pfizer and BioNTech for 40 million doses of the Pfizer-BioNTech COVID-19 vaccine.

The Covax initiative was established by leading public health agencies, including the World Health Organization, to provide governments with early access to a large portfolio of COVID-19 vaccines. The new advance purchase agreement secures 40 million doses to be delivered throughout 2021.

The first doses are expected to be delivered in the first quarter of the year, and Pfizer and BioNTech will provide the vaccine to 92 low- and middle-income countries for not-for-profit pricing.

Terms of the agreement were not disclosed. The delivery is subject to supply agreements under the Covax Facility structure.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?